TAE-226

N/A

Report date: 2023/05/22 10:19:14
NME

Base Information

Drug NameTAE-226
Drug Alias NameTAE-226
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase inhibitorsInsulin-like growth factor I receptor antagonists
TargetsFocal adhesion kinaseInsulin-like growth factor I receptor
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A